Not yet a member?
Here’s the podcast of the Q&A portion of the excellent webinar with Dr. Pennell on Molecular Markers in Management of NSCLC.
dr-pennell-molecular-markers-qa-audio-podcast
dr-pennell-molecular-markers-qa-transcript
dr-pennell-molecular-markers-qa-figures
Podcast: Play in new window | Download
0 CommentsThe IPASS trial that randomized Asian never-smoking or light previously smoking patients with previously untreated advanced NSCLC to either standard chemo or the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) inhibitor Iressa (gefitinib) is widely considered among the most important and standard-changing trials of the last few years in the field of lung [...]
14 CommentsOncologists often have their own ideas about how effective or ineffective a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) (Tarceva (erlotinib) or Iressa (gefitinib)) is compared with standard chemotherapy options. We’ve seen a lot of new information emerge in the field over the last few years, and we now have evidence that [...]
6 CommentsWe know that many people interested in the topics we discuss in our webinars may not be able to attend the live programs, but we’re committed to offering our content to people as easily as possible. Accordingly, here is the podcast version of Dr. Pennell’s very well received presentation on a range of molecular [...]
Podcast: Play in new window | Download
0 CommentsThis is a continuation of the round table format, discussing real life case management with my colleagues who are lung cancer experts at other institutions, This case is the second half of discussion centered around a never-smoking Asian woman who doesn’t have an EGFR mutation, and specifically the decision-making process of what first line chemotherapy-based treatment to [...]
Podcast: Play in new window | Download
2 CommentsAs one more way to reach patients and caregivers everywhere, we’re going to do our first live “webinar” (as in, web-based seminar) in two weeks. Our own beloved Dr. Nathan Pennell, of Cleveland Clinic and GRACE faculty fame, will present a talk with slides on “The Evolving Role of Molecular Markers in Managing Non-Small Cell [...]
2 CommentsHere is the first podcast of what we plan will be an ongoing series of round table discussions with cancer experts about real case scenarios and how we make decisions in practice. My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical [...]
Podcast: Play in new window | Download
1 CommentsI’m fortunate to practice at Moffitt, where Dr. Gerold Bepler and Dr. George Simon pioneered a molecularly directed approach to front-line chemotherapy in NSCLC. Data from the phase II clinical trial demonstrated impressive median survival for a platinum-based doublet: 13.3 months. The schema of the MADeIT clinical trial is shown below and I’m happy to [...]
5 CommentsIt seems obvious: environmental tobacco smoke (ETS)/passive smoke exposure from being around smokers, can be harmful and may cause cancer in never-smokers. A new paper in the Journal of Clinical Oncology by Lee and colleagues from Korea actually offers some evidence that highlights this, showing that never-smokers in Korea were less likely to have an [...]
6 CommentsDr. George Simon, medical oncologist and Director of the Thoracic Oncology Program at Fox Chase Cancer Center in Philadelphia, has been kind enough to sit down for an interview with me earlier this year, which was made into a podcast several months ago. More recently, he participated in our NSCLC Patient Education, sponsored by OSI [...]
Podcast: Play in new window | Download
0 Comments